NCMHCE - National Clinical Mental Health Counseling Examination Psychopharmacology and Co-occurring Disorders Questions and Answers — Questions and Answers
Question 1: A 48-year-old client with co-occurring diagnoses of severe Alcohol Use Disorder and Post-Traumatic Stress Disorder (PTSD) is prescribed clonazepam (a benzodiazepine) by their primary care physician to manage anxiety and insomnia. The client reports to their counselor that the medication initially helped but now seems less effective at the prescribed dose. What is the MOST likely psychopharmacological reason for this phenomenon?
- The client has developed a paradoxical reaction to the medication.
- The medication is primarily metabolized by the liver, which is likely compromised.
- Cross-tolerance has developed between alcohol and the benzodiazepine. (Correct answer)
- The client's PTSD symptoms are inherently resistant to anxiolytic medication.
Correct answer: Cross-tolerance has developed between alcohol and the benzodiazepine.
Alcohol and benzodiazepines are both central nervous system depressants that act on the GABA-A receptor. Chronic, heavy use of alcohol leads to tolerance, where the brain adapts and requires more of the substance to achieve the same effect. This tolerance 'crosses over' to other drugs that work on the same neural system, like benzodiazepines, making them less effective at standard doses for a person with a history of severe alcohol use.
Question 2: A counselor is part of a treatment team for a client diagnosed with Bipolar I Disorder and Amphetamine-Type Stimulant Use Disorder. The client's psychiatrist is considering prescribing a mood stabilizer. Which of the following statements reflects the counselor's MOST appropriate role regarding the client's medication?
- Advising the client that lithium is the 'gold standard' and they should request it specifically.
- Monitoring and documenting the client's mood fluctuations, medication adherence, and any reported side effects to share with the treatment team. (Correct answer)
- Recommending the client discontinue the medication if they experience a relapse in stimulant use.
- Explaining the detailed neurochemical mechanism of action for various mood stabilizers to the client.
Correct answer: Monitoring and documenting the client's mood fluctuations, medication adherence, and any reported side effects to share with the treatment team.
A clinical mental health counselor's scope of practice does not include prescribing, recommending specific medications, or advising on dosage. However, the counselor plays a critical collaborative role by observing the client's progress in therapy, monitoring medication adherence, tracking symptoms and side effects, and communicating these observations to the prescribing physician. This information is vital for effective medication management.
Question 3: A client with Opioid Use Disorder and Major Depressive Disorder is beginning Medication-Assisted Treatment (MAT). They are prescribed a medication that is a partial opioid agonist, designed to reduce cravings and withdrawal symptoms while having a 'ceiling effect' that lowers the risk of overdose. Which medication fits this description?
- Naltrexone
- Methadone
- Disulfiram
- Buprenorphine (Correct answer)
Correct answer: Buprenorphine
Buprenorphine is a partial opioid agonist. It activates the opioid receptors in the brain, but to a much lesser degree than a full agonist like methadone or heroin. This activation is enough to prevent withdrawal and reduce cravings. The 'ceiling effect' means that after a certain dose, its effects do not increase, which significantly reduces the risk of respiratory depression and overdose.
Question 4: Which of the following represents the most significant risk of prescribing a benzodiazepine, such as alprazolam, for a client with Generalized Anxiety Disorder who also has an active, untreated Alcohol Use Disorder?
- The high potential for dangerous synergistic effects and cross-addiction. (Correct answer)
- A high probability of inducing a manic episode.
- The likelihood of the medication causing severe gastrointestinal distress.
- The risk of serotonin syndrome when alcohol and alprazolam are combined.
Correct answer: The high potential for dangerous synergistic effects and cross-addiction.
Both alcohol and benzodiazepines are central nervous system (CNS) depressants. When taken together, they have a synergistic effect, meaning their combined impact on CNS depression (e.g., respiratory depression) is greater than the sum of their individual effects, which can be fatal. Furthermore, because they act on similar neural pathways, there is a very high risk of cross-addiction and physical dependence.
Question 5: A 30-year-old client is stabilized in treatment for both Schizophrenia and Cannabis Use Disorder. The client's care is managed by a single team of professionals in one location, where they receive antipsychotic medication management, individual therapy addressing both psychosis and substance use, and case management services. This model of care is best described as:
- Sequential treatment
- Integrated treatment (Correct answer)
- Parallel treatment
- Tertiary treatment
Correct answer: Integrated treatment
Integrated treatment is the evidence-based best practice for co-occurring disorders. It is characterized by the same clinicians or team providing both mental health and substance abuse services at the same time and in the same setting. This contrasts with sequential (treating one disorder, then the other) or parallel (treating both at the same time but by different providers in different systems) models.
Question 6: A client with a co-occurring diagnosis of Alcohol Use Disorder, now in sustained remission, and persistent depressive disorder is being treated with sertraline (an SSRI). The client's psychiatrist wants to add a medication to help maintain alcohol abstinence by reducing cravings. Which FDA-approved medication accomplishes this by modulating glutamate transmission rather than by blocking opioid receptors?
- Naltrexone
- Disulfiram
- Acamprosate (Correct answer)
- Buspirone
Correct answer: Acamprosate
Acamprosate is believed to work by stabilizing chemical signaling in the brain that is disrupted by long-term, heavy alcohol use, specifically by normalizing glutamate and GABA neurotransmitter systems. This helps reduce the protracted withdrawal symptoms like insomnia, anxiety, and restlessness that can lead to relapse. Unlike Naltrexone, it does not block opioid receptors, and unlike Disulfiram, it does not create an aversive reaction to alcohol.
NCMHCE - National Clinical Mental Health Counseling Examination Psychopharmacology and Co-occurring Disorders Questions and Answers
A 48-year-old client with co-occurring diagnoses of severe Alcohol Use Disorder and Post-Traumatic Stress Disorder (PTSD) is prescribed clonazepam (a benzodiazepine) by their primary care physician to manage anxiety and insomnia.
The client reports to their counselor that the medication initially helped but now seems less effective at the prescribed dose.
What is the MOST likely psychopharmacological reason for this phenomenon?